STAT News

STAT+: Pharmalittle: We’re reading about an FDA rejection, 340B court battles, and more

The FDA rejected a radiopharmaceutical therapy because of manufacturing issues, halting what would have been a competitor for Novartis

Por STAT News

1 minuto de lectura
Compartir
STAT+: Pharmalittle: We’re reading about an FDA rejection, 340B court battles, and more
STAT+: Pharmalittle: We’re reading about an FDA rejection, 340B court battles, and more

¿Tiene noticias que compartir con el sector de eventos?

Envíe un comunicado de prensa o una noticia y llegue a miles de profesionales del sector de eventos.

Contáctenos→

Más en Health Tech

Perspectivas relacionadas